FIELD: pharmaceutics and medicine.
SUBSTANCE: use of polymorph 1 of fluticasone propionate having a crystalline form (form A) which is characterized by an X-ray powder pattern including characteristic peaks at approximately 7.8, 15.7, 20.8, 23.7, 24.5 and 32.5 °C and additional peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1 and 34.3 °C, where said fluticasone propionate is in the form of nanocrystals having a [001] crystallographic axis substantially perpendicular to the surface that determines the thickness of the nanocrystals, for the preparation of an ophthalmic composition for topical use for the treatment or alleviation of an inflammatory condition of the eye selected from inflammatory blepharitis and dry eye.
EFFECT: effective treatment or alleviation of an inflammatory eye condition such as inflammatory blepharitis and dry eye.
7 cl, 42 dwg, 43 tab, 15 ex
